Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
The Oncologist
|
November 25, 2022
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
Hiromichi Matsuoka, Junji Tsurutani, Yasutaka Chiba, et al.
BMC Medical Education
|
February 11, 2021
A model six-month workshop for developing systematic review protocols at teaching hospitals: action research and scholarly productivity
Hiraku Tsujimoto, Yuki Kataoka, Yukihito Sato, et al.
Oncology Letters
|
August 7, 2023
Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
Yoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.
Journal of Pain and Symptom Management
|
June 30, 2019
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)
Hiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 26, 2019
Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) study
Hiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.
Kidney International
|
January 5, 2024
Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure
Sara N Davison, Wolfgang Pommer, Mark A Brown, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
The Oncologist
|
November 25, 2022
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
Hiromichi Matsuoka, Junji Tsurutani, Yasutaka Chiba, et al.
BMC Medical Education
|
February 11, 2021
A model six-month workshop for developing systematic review protocols at teaching hospitals: action research and scholarly productivity
Hiraku Tsujimoto, Yuki Kataoka, Yukihito Sato, et al.
Oncology Letters
|
August 7, 2023
Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
Yoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.
Journal of Pain and Symptom Management
|
June 30, 2019
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)
Hiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 26, 2019
Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) study
Hiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.
Kidney International
|
January 5, 2024
Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure
Sara N Davison, Wolfgang Pommer, Mark A Brown, et al.
Page
of 2